Please note that LIDDS will disclose information in Press releases only in English going forward. Vänligen notera att LIDDS fortsättningsvis kommer att offentliggöra pressmeddelanden endast på engelska. Erik Penser temadag med bolag i cancerforskningens frontlinje, Stockholm, October 6, 2020, Monica Wallter, CEO LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months. Visitingadress: Virdings allé 32b, Uppsala LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.comPress releases
LIDDS has decided to apply for listing of the company’s shares on Nasdaq Stockholm Main Market in 2021 Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot LIDDS AB (publ) announces the appointment of Nina Herne as CEO
LIDDS Delårsrapport januari – september 2020 A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development LIDDS publishes prospectus in connection with forthcoming rights issue LIDDS will participate in Redeye’s Fight Cancer Seminar on March 10Events
Company Analysis
Photo Library
Lidds
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.comSubscribe for news
Press releases
LIDDS has decided to apply for listing of the company’s shares on Nasdaq Stockholm Main Market in 2021 Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot LIDDS AB (publ) announces the appointment of Nina Herne as CEO LIDDS Delårsrapport januari – september 2020 A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development LIDDS publishes prospectus in connection with forthcoming rights issue LIDDS will participate in Redeye’s Fight Cancer Seminar on March 10
press
events
analysis
